2013-09-30 18:03:01 -
Mechelen, Belgium; 30 September 2013 - Galapagos NV (Euronext: GLPG) announced
today that it has received a transparency notification from Delta Lloyd N.V.
pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007 on
the disclosure of major shareholdings in issuers whose shares are admitted to
trading on a regulated market).
Galapagos received a transparency notification on 27 September 2013 from Delta
Lloyd N.V. Delta Lloyd notified that on 26 September 2013 entities under their
control held 2,954,890 shares, which represent 9.93% of the current 29,755,302
outstanding Galapagos shares. This represents a reduction of Delta Lloyd's
participation by 0.15% compared to the previous notification of 3,000,000 shares
by Delta Lloyd Asset Management N.V.
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of five Phase 2 (two led by GSK), one Phase 1, six pre-
clinical, and more than 20 discovery small-molecule and antibody programs in
cystic fibrosis, inflammation, antibiotics, metabolic disease, and other
AbbVie and Galapagos have an agreement in CF where they work collaboratively to
develop and commercialize oral drugs that address two mutations in the CFTR
gene, the G551D and F508del mutation. In the field of inflammation, AbbVie and
Galapagos have a worldwide license agreement whereby AbbVie will be responsible
for further development and commercialization of GLPG0634 after Phase 2B.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, currently
in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's disease.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has 800 employees and operates facilities in five countries, with
global headquarters in Mechelen, Belgium. Further information at: www.glpg.com
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks,"
"estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Delta Lloyd notify of 9.93% shareholding in Galapagos :
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE